Increase in repulsive guidance molecule-a (RGMa) in lacunar and cortical stroke patients is related to the severity of the insult

Aijaz Parray, Naveed Akhtar, Ghulam Jeelani Pir, Sajitha V. Pananchikkal, Raheem Ayadathil, Fayaz Ahmad Mir, Reny Francis, Ahmed Own, Ashfaq ShuaibScientific 2022 · DOI

Abstract

Repulsive guidance molecule-a (RGMa) inhibits angiogenesis and increases inflammation. Animal models of cerebral ischemia have shown that an increased expression of RGMa leads to larger infarction and its inhibition attenuates effects of ischemia. We report on the relationship of RGMa to stroke types and severity. This is a prospective study in patients admitted to the stroke service in Qatar. We collected the clinical determinants, including NIHSS at admission, imaging and outcome at discharge and 90-days. RGMa levels were determined by measuring mRNA levels extracted from peripheral blood mononuclear cells (PBMCs) within 24 h of onset and at 5 days. There were 90 patients (lacunar: 64, cortical: 26) and 35 age-matched controls. RGMa mRNA levels were significantly higher in the stroke patients: day 1: 1.007 ± 0.13 versus 2.152 ± 0.19 [p < 0.001] and day-5: 3.939 ± 0.36 [p < 0.0001]) and significantly higher in patients with severe stroke (NIHSS ≥ 8) compared to milder symptoms (NIHSS < 8) at day 1 (NIHSS ≥ 8: 2.563 ± 0.36; NIHSS < 8: 1.947 ± 0.2) and day 5 (NIHSS ≥ 8: 5.25 ± 0.62; NIHSS < 8: 3.259 ± 0.419). Cortical stroke patients had marginally higher RGMa mRNA levels compared to lacunar stroke at day 1 (cortical stroke: 2.621 ± 0.46 vs lacunar stroke: 1.961 ± 0.19) and day 5 (cortical stroke: 4.295 ± 0.76 vs lacunar stroke: 3.774 ± 0.39). In conclusion, there is an increase in the level of RGMa mRNA in patients with acute stroke and seen in patients with lacunar and cortical stroke. The increase in RGMa mRNA levels is related to the severity of the stroke and increases over the initial 5 days. Further studies are required to determine the effects of the increase in RGMa on stroke recovery.

Introduction

Following an acute ischemic stroke, the brain's innate repair mechanisms are often obstructed by inhibitory proteins that act as "molecular brakes." These proteins prevent the regrowth of axons and the formation of new blood vessels (angiogenesis), which are critical for functional recovery. One of the most potent inhibitors identified in preclinical research is Repulsive Guidance Molecule-a (RGMa).

While animal models have demonstrated that blocking RGMa can reduce infarct size and improve neurological outcomes, clinical evidence in humans has remained limited. This study addresses this gap by investigating whether RGMa mRNA levels increase in human stroke patients and whether these levels correlate with the type of stroke (lacunar vs. cortical) or the clinical severity of the insult. Understanding these dynamics is essential for the development of neuroprotective therapies, such as monoclonal antibodies targeting RGMa, which are currently entering clinical trials.

Methods

This prospective study followed 90 acute stroke patients admitted to the Hamad Medical Corporation stroke service in Qatar, alongside 35 age-matched healthy controls.

Clinical and Molecular Assessment

Stroke severity was assessed at admission using the National Institutes of Health Stroke Scale (NIHSS), and functional outcomes were tracked using the modified Rankin Scale (mRS) at 90 days. Molecular analysis involved extracting mRNA from peripheral blood mononuclear cells (PBMCs) at two specific time points: within 24 hours of stroke onset (Day 1) and at Day 5. Quantitative Real-Time PCR (RT-qPCR) was utilized to measure RGMa mRNA expression, with data normalized against GAPDH to determine relative fold units of increase.

Imaging and Classification

Magnetic resonance imaging (MRI) allowed researchers to categorize strokes into lacunar (small, deep vessel) or cortical (large surface vessel) subtypes. Additionally, the presence of pre-existing small vessel disease (SVD) was recorded to determine if chronic vascular decline influenced the acute RGMa response.

Key Results

Temporal and Subtype Dynamics

The study revealed a significant systemic increase in RGMa mRNA levels following a stroke. Unlike many biomarkers that peak early and then decline, RGMa levels continued to climb throughout the first week. On Day 1, stroke patients exhibited RGMa levels of 2.152 ± 0.19 fold units compared to 1.007 ± 0.13 in controls (p < 0.001). By Day 5, this expression nearly doubled to 3.939 ± 0.36 (p < 0.0001).

RGMa mRNA expression levels across stroke subtypes and time points.

This increase was universal across stroke subtypes. While cortical strokes—which generally involve a larger volume of brain tissue—showed marginally higher levels than lacunar strokes, both groups demonstrated a significant spike compared to baseline. This indicates that even small-vessel lacunar insults trigger a robust systemic RGMa response.

Correlation with Clinical Severity

A primary finding of the study was the direct correlation between clinical severity and molecular expression. Patients with more severe strokes (NIHSS ≥ 8) showed significantly higher RGMa levels than those with milder symptoms (NIHSS < 8) at both time points.

Correlation between stroke severity (NIHSS) and RGMa mRNA expression at Day 1 and Day 5.

Pearson correlation analysis confirmed a significant relationship between NIHSS scores and RGMa levels at Day 1 (p = 0.023) and Day 5 (p = 0.013), suggesting that RGMa expression serves as a molecular mirror of the clinical severity of the brain injury.

Discussion and Conclusion

The findings suggest that the inhibitory environment in the brain may intensify in the days following the initial injury, as evidenced by the rising RGMa levels. Interestingly, the presence of pre-existing small vessel disease (SVD) did not significantly alter the RGMa response, suggesting the spike is a specific reaction to the acute ischemic event rather than chronic vascular pathology.

Limitations and Future Directions

The study's limitations include a relatively small sample size for cortical stroke patients (n=26) and a short observation window of five days. It remains unknown when RGMa levels return to baseline or how long the "inhibitory window" for repair remains open. Future research should focus on long-term tracking of RGMa levels and clinical trials to determine if inhibiting this surge can translate into improved functional recovery for patients.

In conclusion, RGMa mRNA levels increase significantly in the acute phase of both lacunar and cortical strokes and correlate with clinical severity, identifying RGMa as a promising biomarker and therapeutic target for post-stroke neuroprotection.

Summary updated

Abstract

Repulsive guidance molecule-a (RGMa) inhibits angiogenesis and increases inflammation. Animal models of cerebral ischemia have shown that an increased expression of RGMa leads to larger infarction and its inhibition attenuates effects of ischemia. We report on the relationship of RGMa to stroke types and severity. This is a prospective study in patients admitted to the stroke service in Qatar. We collected the clinical determinants, including NIHSS at admission, imaging and outcome at discharge and 90-days. RGMa levels were determined by measuring mRNA levels extracted from peripheral blood mononuclear cells (PBMCs) within 24 h of onset and at 5 days. There were 90 patients (lacunar: 64, cortical: 26) and 35 age-matched controls. RGMa mRNA levels were significantly higher in the stroke patients: day 1: 1.007 ± 0.13 versus 2.152 ± 0.19 [p < 0.001] and day-5: 3.939 ± 0.36 [p < 0.0001]) and significantly higher in patients with severe stroke (NIHSS ≥ 8) compared to milder symptoms (NIHSS < 8) at day 1 (NIHSS ≥ 8: 2.563 ± 0.36; NIHSS < 8: 1.947 ± 0.2) and day 5 (NIHSS ≥ 8: 5.25 ± 0.62; NIHSS < 8: 3.259 ± 0.419). Cortical stroke patients had marginally higher RGMa mRNA levels compared to lacunar stroke at day 1 (cortical stroke: 2.621 ± 0.46 vs lacunar stroke: 1.961 ± 0.19) and day 5 (cortical stroke: 4.295 ± 0.76 vs lacunar stroke: 3.774 ± 0.39). In conclusion, there is an increase in the level of RGMa mRNA in patients with acute stroke and seen in patients with lacunar and cortical stroke. The increase in RGMa mRNA levels is related to the severity of the stroke and increases over the initial 5 days. Further studies are required to determine the effects of the increase in RGMa on stroke recovery.
BibTeX
@inproceedings{parray2022increase,
  author = {Aijaz Parray and Naveed Akhtar and Ghulam Jeelani Pir and Sajitha V. Pananchikkal and Raheem Ayadathil and Fayaz Ahmad Mir and Reny Francis and Ahmed Own and Ashfaq Shuaib},
  title = {{Increase in repulsive guidance molecule-a (RGMa) in lacunar and cortical stroke patients is related to the severity of the insult}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-24481-2},
}
Figure